Swiss drug maker Roche posts 7 percent profit drop

July 24, 2014

(AP)—Swiss drugmaker Roche Holding AG on Thursday posted a net profit drop of 7 percent compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units.

The world's biggest manufacturer of , which reports earnings every six months, said it had 5.641 billion Swiss francs ($6.25 billion) in net income from April to June, down from 6.047 billion francs in the comparable period of 2013.

The Basel, Switzerland-based company said its first-half sales were 22.974 billion francs, down 1 percent from 23.295 billion francs from a year ago.

It reported impairment charges of 414 million francs in tissue diagnostics and said the Swiss franc was stronger against most currencies in the first half of the year, particularly against the dollar, the yen and several Latin American currencies.

"The overall impact is strongly negative on the results expressed in Swiss francs compared to constant exchange rates, with a 6-8 percentage point impact on sales," the company reported.

In a statement, Chief Executive Severin Schwan described the company's first half as "good," driven mainly by its cancer medicines, especially new breast treatments Perjeta and Kadcyla, and by its diagnostics products.

Roche said it expects low to mid-single digit growth in overall sales for the year, and to further increase its dividend.

"Based on our half year performance, I am confident that we will meet our full-year targets," Schwan said.

Explore further: Roche sees net profit swell amid cancer drug success

Related Stories

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013

Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Cancer drugs give Roche a 2012 profit boost

January 30, 2013

Growing demand for its cancer medicines and diagnostic tests used by clinical laboratories helped Swiss drug maker Roche Holding AG post a modest 2.4 percent increase in full-year profits.

Novartis Q4 net profit rises to $2.0 billion

January 29, 2014

Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Roche profits drop on one-off costs

July 26, 2012

(AP) — One-off charges at Swiss drugmaker Roche Holding AG on Thursday pushed first-half net profits down 17 percent, but strong sales of cancer drugs and cost-cutting contributed to a rise in core operating figures.

Swiss pharma Novartis ups full-year sales outlook (Update)

October 22, 2013

Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Recommended for you

Swiss unveil stratospheric solar plane

December 7, 2016

Just months after two Swiss pilots completed a historic round-the-world trip in a Sun-powered plane, another Swiss adventurer on Wednesday unveiled a solar plane aimed at reaching the stratosphere.

Solar panels repay their energy 'debt': study

December 6, 2016

The climate-friendly electricity generated by solar panels in the past 40 years has all but cancelled out the polluting energy used to produce them, a study said Tuesday.

Wall-jumping robot is most vertically agile ever built

December 6, 2016

Roboticists at UC Berkeley have designed a small robot that can leap into the air and then spring off a wall, or perform multiple vertical jumps in a row, resulting in the highest robotic vertical jumping agility ever recorded. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.